Ocular Hypertension Treatment Study (OHTS) (OHTS)

Clinical Trial ID NCT00000125

PubWeight™ 85.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00000125

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 16.89
2 The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 11.38
3 The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999 3.30
4 Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004 2.39
5 Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology 2012 2.35
6 Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001 2.35
7 Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2006 2.28
8 Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010 2.14
9 The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004 2.03
10 Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005 1.80
11 Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006 1.80
12 Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol 2003 1.76
13 Smartphones in ophthalmology. Indian J Ophthalmol 2012 1.64
14 Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol 2000 1.62
15 The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology 2010 1.61
16 Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Arch Ophthalmol 2004 1.49
17 Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology 2002 1.46
18 Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology 2006 1.44
19 Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol 2008 1.43
20 The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol 2002 1.27
21 Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma. Ophthalmology 2011 1.23
22 Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol 2005 1.20
23 Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol 2010 1.18
24 The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology 2006 1.16
25 Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study. Ophthalmology 2009 1.06
26 Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol 2000 1.06
27 The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors. Am J Ophthalmol 2004 1.06
28 Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study. Ophthalmology 2010 1.05
29 Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol 2006 1.05
30 Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci 2012 1.03
31 Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet 2016 1.02
32 Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea 2006 0.99
33 The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci 2012 0.98
34 Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology 2008 0.98
35 Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma 2007 0.97
36 Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005 0.95
37 Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci 2006 0.93
38 Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci 2013 0.91
39 Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004 0.88
40 The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals. Ophthalmology 2008 0.85
41 Rate of visual field progression in eyes with optic disc hemorrhages in the ocular hypertension treatment study. Arch Ophthalmol 2012 0.85
42 Seasonal changes in visual field sensitivity and intraocular pressure in the ocular hypertension treatment study. Ophthalmology 2013 0.84
43 The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology 2010 0.83
44 A joint-modeling approach to assess the impact of biomarker variability on the risk of developing clinical outcome. Stat Methods Appt 2011 0.83
45 The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model. Ophthalmology 2012 0.82
46 Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension. Arch Ophthalmol 2010 0.81
47 Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmol Ther 2016 0.80
48 The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Am J Ophthalmol 2013 0.79
49 Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2007 0.79
50 Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open-Angle Glaucoma. J Biom Biostat 2015 0.79
51 The 10-year incidence of glaucoma among patients with treated and untreated ocular hypertension. Arch Ophthalmol 2011 0.78
52 Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. Ophthalmology 2014 0.77
53 A Joint Model for Prognostic Effect of Biomarker Variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). JP J Biostat 2011 0.77
54 Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol 2005 0.77
55 Conditional Asymptotic Inference for the Kernel Association Test. Bioinformatics 2017 0.75
56 Diabetes and glaucoma. Arch Ophthalmol 2008 0.75
57 Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension. Invest Ophthalmol Vis Sci 2015 0.75
58 Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Software Program in Ophthalmologists-in-Training. Am J Ophthalmol 2016 0.75
59 Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. Ophthalmology 2016 0.75
60 Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses. Invest Ophthalmol Vis Sci 2016 0.75
61 Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2016 0.75
62 Comparing glaucomatous disc change using stereo disc viewing and the MatchedFlicker programme in glaucoma experts and trainees. Br J Ophthalmol 2017 0.75
63 Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. BMC Med Res Methodol 2017 0.75
64 A gene-based test of association through an orthogonal decomposition of genotype scores. Hum Genet 2017 0.75
Next 100